康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

已收盘 01-13 16:08:13

120.600

-5.500

-4.36%

最高124.200	最低118.300	成交量1,451万
今开121.800	昨收126.100	日振幅4.68%
总市值1,111亿	流通市值1,111亿	总股本9.21亿
成交额17.58亿	换手率1.58%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":120.6,"timestamp":1768291693010,"preClose":126.1,"halted":0,"volume":14510218,"delay":0,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"已收盘","change":-5.5,"latestTime":"01-13 16:08:13","open":121.8,"high":124.2,"low":118.3,"amount":1757732719,"amplitude":0.046788,"askPrice":120.6,"askSize":42000,"bidPrice":120.4,"bidSize":23000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":126.1,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":2.120872,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2603857533","title":"依沃西首个海外适应症BLA向FDA提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2603857533","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603857533?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:56","pubTimestamp":1768269410,"startTime":"0","endTime":"0","summary":"每经AI快讯，据康方生物公众号消息，1月12日，康方生物自主研发的全球首创PD-1/VEGF双抗依沃西海外合作伙伴SummitTherapeutics宣布，已于2025年第四季度向美国食品药品监督管理局（FDA）提交了依沃西的一项生物制品许可申请，用于联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞肺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133616872722.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133616872722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B5MMRT66.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","LU2399975544.HKD","LU1720050803.USD","LU2488822045.USD","LU0348783233.USD","LU2476274308.USD","LU0417516738.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348735423.USD","LU0417516571.SGD","LU0348766576.USD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","LU0348825331.USD","BK1574","LU0348827113.USD","BK1161","LU1961090484.USD","LU0561508036.HKD","LU2476274720.SGD","LU0634319403.HKD"],"gpt_icon":0},{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02172","09939","09926","BK1100","03933","01276","09995","BK1617","BK1141","02615","BK1515","BK1574","02228","BK1161"],"gpt_icon":0},{"id":"2602327262","title":"每日卖空追踪 | 康方生物 01月09日卖空量成交26.2万股，卖空比例为5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327262","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602327262?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:30","pubTimestamp":1767947442,"startTime":"0","endTime":"0","summary":"康方生物北京时间01月09日，跌0.47%，卖空量成交26.2万股，较上一交易日减少59.38%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109164039a70680f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109164039a70680f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0634319403.HKD","LU0348766576.USD","LU2476274308.USD","LU0561508036.HKD","LU0348827113.USD","BK1161","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348767384.USD","LU2476274720.SGD","09926","LU2488822045.USD","LU2778985437.USD","LU0417516902.SGD","LU2399975544.HKD","IE00B543WZ88.USD","LU1720050803.USD","LU0348783233.USD","LU1794554557.SGD","BK1574","LU0540923850.HKD","LU0417516738.SGD","LU0348784397.USD","LU0348825331.USD","LU0348735423.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"1128958057","title":"港交所推出六只新股票期权，包括紫金黄金国际、老铺黄金、地平线机器人等，1月19日开始买卖","url":"https://stock-news.laohu8.com/highlight/detail?id=1128958057","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128958057?lang=zh_cn&edition=full","pubTime":"2026-01-09 13:19","pubTimestamp":1767935995,"startTime":"0","endTime":"0","summary":" $香港交易所(00388)$ 宣布将推出六只新股票期权（仅限每月到期期权）并于2026 年 1 月 19 日（星期一）（「开始交易日」）开始买卖，包括紫金黄金国际、老铺黄金、地平线机器人等。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/8bff26889e5f42acbe22c7bd91f5be44","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/8bff26889e5f42acbe22c7bd91f5be44"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"836eccfa0ddb96db25d89773a6907fbb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港交所推出六只新股票期权，包括紫金黄金国际、老铺黄金、地平线机器人等，1月19日开始买卖","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02259","06181","09660","06160","09926"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1934453819.USD","LU0307460666.USD","LU0501845795.SGD","LU1152091168.USD","LU0417516571.SGD","01093","LU0039217434.USD","BK1589","LU0561508036.HKD","01877","IE0008369823.USD","LU0516422440.USD","LU1807302812.USD","09926","LU2476274720.SGD","LU0043850808.USD","BK0012","LU2148510915.USD","02142","LU1064131003.USD","LU2097828474.EUR","LU1960683339.HKD","01801","09995","IE00B5MMRT66.SGD","LU3063872942.SGD","06978","LU1979443071.USD","02616","06160","LU1993786604.SGD","BK0183","BK1500","LU0588546209.SGD","159992","LU1242518857.USD","LU2097828805.USD","LU0067412154.USD","01177","06185","09688","LU1226287792.SGD","02269","LU1328277881.USD","LU0516422952.EUR","LU0502904849.HKD","601688","BK1141","LU0315179316.USD"],"gpt_icon":0},{"id":"2602318472","title":"康方生物01月08日主力净流出522.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318472","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602318472?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:16","pubTimestamp":1767860162,"startTime":"0","endTime":"0","summary":"01月08日, 康方生物股价跌0.77%，报收128.20元，成交金额6.2亿元，换手率0.53%，振幅2.71%，量比0.76。康方生物今日主力资金净流出522.5万元，上一交易日主力净流入1.2亿元。该股近5个交易日上涨12.39%，主力资金累计净流入1.6亿元；近20日主力资金累计净流入1.0亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162840a7022a90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162840a7022a90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348784397.USD","LU0540923850.HKD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0348825331.USD","BK1161","LU0348767384.USD","LU0348766576.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU0417516571.SGD","LU2476274308.USD","LU0348735423.USD","LU1794554557.SGD","LU2399975544.HKD","LU2476274720.SGD","LU1720050803.USD","LU0417516902.SGD","09926","LU0348783233.USD","LU2488822045.USD","LU0634319403.HKD","LU1961090484.USD","LU0417516738.SGD","LU0348827113.USD","BK1574","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2602318256","title":"万联证券：国内药企崭露头角 前沿平台与出海潜力成投资主脉","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318256","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602318256?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:26","pubTimestamp":1767842814,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，万联证券发布研报称，2025 年FDA 批准新药的创新“质量”提升和技术平台多元化，国内药企崭露头角。万联证券主要观点如下：事件2025 年，FDA 药品评价与研究中心共批准了46 款新药，虽然获批数量相较于2024 年及2023 年均有所下降，但是获批新药的类型丰富且创新性较高。国内药企中山康方生物医药有限公司的派安普利单抗和迪哲（江苏）医药股份有限公司的舒沃替尼获得FDA 批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108115310a7014452&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108115310a7014452&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348827113.USD","LU0561508036.HKD","LU0417516571.SGD","LU2476274308.USD","LU0348766576.USD","09926","LU1961090484.USD","LU0348783233.USD","IE00B543WZ88.USD","LU0417516738.SGD","BK1574","LU0540923850.HKD","LU2399975544.HKD","BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU2476274720.SGD","LU0634319403.HKD","LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516902.SGD","LU0348825331.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2601351333","title":"交易总额突破1300亿美元！2025年全球创新药BD交易全景分析及趋势预判","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351333","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351333?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:55","pubTimestamp":1767837325,"startTime":"0","endTime":"0","summary":"本文将基于药渡咨询的深度调研数据，对2025年全球及中国创新药BD交易的全景进行深度剖析，并对未来五年的发展趋势进行前瞻性预判。全景回顾：全球与中国BD交易的双向奔赴1.交易规模：中国领跑全球增长2025年，全球生物医药BD授权交易呈现出显著的回暖与扩张态势。此次交易总金额高达42.3亿美元，直接推动荣昌生物股价在两周内涨幅超105%。结 语2025年标志着中国创新药BD交易从“量变”走向“质变”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09926","02615","09995","06978"],"gpt_icon":0},{"id":"2601808383","title":"港股概念追踪|国家药监局优化临床急需境外已上市药品审评审批    创新药高景气度延续（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808383","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601808383?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:07","pubTimestamp":1767830855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de4be8e90342c7505536e308e38cab46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","LU0417516902.SGD","LU0348767384.USD","LU0417516571.SGD","LU0348766576.USD","00013","LU2778985437.USD","LU0561508036.HKD","BK1574","LU2476274720.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU1720050803.USD","BK1588","LU0417516738.SGD","LU2476274308.USD","159992","IE00B543WZ88.USD","BK1191","LU0540923850.HKD","LU0348827113.USD","LU0348784397.USD","BK1161","LU2488822045.USD","LU0348735423.USD","LU1961090484.USD","06978","IE00B5MMRT66.SGD","LU1794554557.SGD","BK1587","LU0348825331.USD","09926","LU0634319403.HKD"],"gpt_icon":0},{"id":"2601316386","title":"3500万美元到账后，宜明昂科超20亿美元BD合作终止，创始人田文志：美国临床推进缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2601316386","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601316386?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:19","pubTimestamp":1767784795,"startTime":"0","endTime":"0","summary":"宜明昂科为何与美国药企终止协议？此次终止不影响宜明昂科已从Axion收到的3500万美元首付款和里程碑付款。临床试验进展乏力成为此次合作终止的导火索。去年8月是宜明昂科最后一次收到BD交易款项，过往五次总计金额为3500万美元，这也是此次交易终止时不可退还的款项。随着BD款项陆续到账，双方的合作项目也在持续推进。但实际上，在2026年开年不到一周，宜明昂科与Instil Bio双方就终止了合作。据公开资料，其于2025年4月开始担任这一职位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516571.SGD","LU0348767384.USD","LU1720050803.USD","LU0348827113.USD","BK1161","LU0540923850.HKD","LU0561508036.HKD","LU0348783233.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU2488822045.USD","01541","BK1574","TIL","IE00BPRC5H50.USD","LU0348735423.USD","LU2399975544.HKD","LU2476274308.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0417516902.SGD","09926","LU2778985437.USD","LU0348766576.USD","LU0348784397.USD","LU1961090484.USD","LU0348825331.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2601386393","title":"每日卖空追踪 | 康方生物 01月07日卖空量成交49.4万股，卖空比例为4.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601386393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601386393?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774644,"startTime":"0","endTime":"0","summary":"康方生物北京时间01月07日，涨7.31%，卖空量成交49.4万股，较上一交易日减少40.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163646a4a6e979&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163646a4a6e979&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348784397.USD","LU0540923850.HKD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0348825331.USD","BK1161","LU0348767384.USD","LU0348766576.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU0417516571.SGD","LU2476274308.USD","LU0348735423.USD","LU1794554557.SGD","LU2399975544.HKD","LU2476274720.SGD","LU1720050803.USD","LU0417516902.SGD","09926","LU0348783233.USD","LU2488822045.USD","LU0634319403.HKD","LU1961090484.USD","LU0417516738.SGD","LU0348827113.USD","BK1574","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2601760808","title":"港股创新药ETF基金涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601760808","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601760808?lang=zh_cn&edition=full","pubTime":"2026-01-07 13:58","pubTimestamp":1767765495,"startTime":"0","endTime":"0","summary":"盘面上，港股创新药表现活跃，凯莱英飙涨7%，泰格医药、昭衍新药、康方生物涨超5%，和黄医药、翰森制药、恒瑞医药等个股涨超4%。截至10：34，热门ETF——港股创新药ETF基金上涨2.85%，冲击三连涨！数据显示，港股创新药ETF基金近60日“吸金”超1亿；最新基金规模达9.39亿元。港股创新药ETF基金跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等领军企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","06821","01276","06127","09926","01801","BK1161","02269","BK1191","03692","02315","00013","BK1574"],"gpt_icon":0},{"id":"2601825895","title":"罕见病创新药内地首张处方药开出 港股通创新药ETF板块迎双重驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2601825895","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601825895?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:27","pubTimestamp":1767756474,"startTime":"0","endTime":"0","summary":"近日，罕见病创新药司拉德帕在中国内地开出了首张处方。创新药物将走入更多寻常百姓家。1月7日，盘中港股创新药持续走强。港股通创新药ETF嘉实盘中涨超3%。2026年我国医药生物行业将正式步入创新药大时代，创新药将逐渐占据我国医药生物行业的主导地位，医保商保的互补结合将长期打开支付空间的天花板，创新药将持续蓬勃发展。创新药产业链行业，受益于创新药的快速发展预计仍将保持良好增长势头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107112826a6fcca5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107112826a6fcca5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","03347","02157","BK1574","BK1576","BK1583","06978","BK1161","09926","BK1141"],"gpt_icon":0},{"id":"2601082346","title":"港股异动 | 康方生物(09926)再涨超6% 依沃西说明书重磅更新 纳入AK112-301研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2601082346","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601082346?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:23","pubTimestamp":1767756230,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物再涨超6%，截至发稿，涨6.15%，报127.8港元，成交额7.89亿港元。消息面上，康方生物宣布，国家药品监督管理局已批准公司自主研发的全球首创PD-1/VEGF双特异性抗体依沃西说明书的一项重要更新：更新纳入了AK112-301/HARMONi-A研究的最终分析数据，即依沃西联合疗法治疗EGFR-TKI治疗后进展的局部晚期或转移性非鳞状非小细胞肺癌取得的具有统计学显著性和临床意义的无进展生存期和总生存期双重获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","LU0348766576.USD","LU2399975544.HKD","LU0634319403.HKD","LU2488822045.USD","LU2476274308.USD","LU0348767384.USD","LU0348783233.USD","09926","LU2778985437.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","LU2476274720.SGD","LU0348827113.USD","LU0348784397.USD","BK1574","LU1961090484.USD","IE00B543WZ88.USD","LU0417516738.SGD","LU0540923850.HKD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","BK1161"],"gpt_icon":0},{"id":"1182469709","title":"康方生物科技（09926）2025年12月股份月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182469709","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182469709?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:01","pubTimestamp":1767690073,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年1月6日发布2025年12月股份变动月报表。报告期内，公司法定股本与已发行股份数均未发生变化，股本维持稳定。截至2025年12月31日，已发行普通股总数为921,143,176股，较上月底无新增发行、购回或注销活动，库存股数量仍为零。鉴于本月内未有任何新增股份发行或回购，公司总体股本状况继续保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：脑机接口有望打开万亿市场空间 需发掘国家政策支持和具有真实需求“真脑机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601868644?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","LU2242644610.SGD","01099","03347","LU0708995583.HKD","02269","LU1046422090.SGD","01801","BK1161","SHPMY","BK1576","LU2125910500.SGD","02607","09926","02359","BK1583","06978","BK1141","BK1574","LU0320764599.SGD","00013","06160","LU0052750758.USD","01177"],"gpt_icon":0},{"id":"2601832208","title":"每日卖空追踪 | 康方生物 01月05日卖空量成交53.9万股，卖空比例为7.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601832208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601832208?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601841,"startTime":"0","endTime":"0","summary":"康方生物北京时间01月05日，涨3.35%，卖空量成交53.9万股，较上一交易日增加43.73%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163842a6f52835&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163842a6f52835&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","LU0634319403.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU2476274720.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0540923850.HKD","BK1161","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","LU1720050803.USD","LU0348767384.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516738.SGD","LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD","BK1574","09926"],"gpt_icon":0},{"id":"2601183224","title":"康方生物01月05日获主力加仓1726.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601183224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601183224?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:15","pubTimestamp":1767600956,"startTime":"0","endTime":"0","summary":"01月05日, 康方生物股价涨3.35%，报收117.10元，成交金额8.6亿元，换手率0.80%，振幅6.44%，量比1.76。康方生物今日主力资金净流入1726.1万元，上一交易日主力净流入325.1万元。该股近5个交易日上涨4.09%，主力资金累计净流出3544.4万元；近20日主力资金累计净流出3848.4万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162214a6f51457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162214a6f51457&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","LU0348827113.USD","LU2488822045.USD","LU1961090484.USD","LU0417516738.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU0561508036.HKD","LU0348735423.USD","LU0634319403.HKD","BK1161","LU1720050803.USD","LU0348784397.USD","LU0348825331.USD","09926","LU0348766576.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU1794554557.SGD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0540923850.HKD","LU2399975544.HKD","BK1574","LU0348783233.USD"],"gpt_icon":0},{"id":"2601029158","title":"恒瑞、百济双雄挺进TOP20！翰森、博泰加速冲刺，11家中国药企入榜，药企市值TOP50大洗牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029158","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029158?lang=zh_cn&edition=full","pubTime":"2026-01-04 21:09","pubTimestamp":1767532195,"startTime":"0","endTime":"0","summary":"2025年的全球药企市值TOP50榜单，不再是跨国巨头的独角戏，11家中国药企集体亮剑。从“还差临门一脚”到稳坐TOP20一隅如果将时间拨回到2023年，中国药企在全球市值TOP50中的处境，常被形容为还差“临门一脚”。而到了2025年末，中国药企在全球药企市值的排行已经发生了实质性改变。恒瑞在2025年中登陆港交所后，其在港股市值一度突破5000亿港元。首次冲进全球制药企业市值TOP20的百济，则代表着另一条路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104212120a6f20aa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104212120a6f20aa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1161","06990","06160","03692","LU0196878994.USD","01801","BK1583","BK1589","09926"],"gpt_icon":0},{"id":"2595877900","title":"中山全市研发经费投入连续三年超百亿，康方生物7个新药已上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2595877900","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595877900?lang=zh_cn&edition=full","pubTime":"2025-12-31 20:36","pubTimestamp":1767184601,"startTime":"0","endTime":"0","summary":"南方财经21世纪经济报道记者郑全怡广州报道12月31日，“十四五”广东成就系列新闻发布会中山专场在广州召开，详细介绍了“十四五”时期中山市经济社会发展的总体情况和主要成就。“十四五”期间，中山地区生产总值连续跨越3500亿、4000亿元关口，预计2025年将突破4200亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512313607147856.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512313607147856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348735423.USD","LU2476274720.SGD","LU1961090484.USD","LU0348766576.USD","LU0540923850.HKD","LU2778985437.USD","LU0634319403.HKD","LU0417516902.SGD","LU0348784397.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","BK1574","LU0348783233.USD","LU0417516738.SGD","09926","LU0417516571.SGD","LU2488822045.USD","LU1720050803.USD","LU2476274308.USD","LU0348827113.USD","IE00B5MMRT66.SGD","BK1161","LU0348767384.USD","IE00BPRC5H50.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0769},{"period":"1month","weight":0.0129},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0008},{"period":"1year","weight":1.2458},{"period":"ytd","weight":0.1159}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.3957},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.019818},{"month":2,"riseRate":0.4,"avgChangeRate":0.029178},{"month":3,"riseRate":0.4,"avgChangeRate":-0.035342},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}